Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Study of Urinary Tumor DNA-Guided Systemic Immunotherapy in Patients With Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

NCT07475403 is registered in ClinicalTrials.gov with Tianjin Medical University Second Hospital as lead sponsor.

NCT NCT07475403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07475403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Study of Urinary Tumor DNA-Guided Systemic Immunotherapy in Patients With Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
Lead sponsor
Tianjin Medical University Second Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
March 16, 2026
Completion date
April 1, 2029
Enrollment
53 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, immunotherapy, liquid biopsy